Trials / Active Not Recruiting
Active Not RecruitingNCT07465679
A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
Real-world Adoption of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction in Treatment With Entresto in Romania (REACT-HFrEF-RO)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to describe the real-world clinical profile, treatment patterns, and guideline alignment of patients with heart failure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan in routine clinical practice in Romania. The study uses secondary use of data, with all analyses conducted on anonymized, pre-existing data collected for routine clinical and administrative purposes.
Conditions
Timeline
- Start date
- 2026-01-28
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
- First posted
- 2026-03-12
- Last updated
- 2026-03-12
Locations
1 site across 1 country: Romania
Source: ClinicalTrials.gov record NCT07465679. Inclusion in this directory is not an endorsement.